A detailed history of Woodline Partners LP transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,003,124 shares of INZY stock, worth $3.03 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,003,124
Previous 1,000,673 0.24%
Holding current value
$3.03 Million
Previous $4.46 Million 17.54%
% of portfolio
0.05%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.31 - $6.0 $10,563 - $14,706
2,451 Added 0.24%
1,003,124 $5.25 Million
Q2 2024

Aug 14, 2024

BUY
$4.33 - $7.31 $487,583 - $823,149
112,606 Added 12.68%
1,000,673 $4.46 Million
Q1 2024

May 15, 2024

BUY
$4.14 - $7.66 $2.43 Million - $4.5 Million
588,067 Added 196.02%
888,067 $6.8 Million
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $813,000 - $1.35 Million
300,000 New
300,000 $1.28 Million
Q2 2023

Aug 14, 2023

BUY
$4.93 - $6.74 $1.42 Million - $1.95 Million
288,827 New
288,827 $1.61 Million

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $121M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.